Amplia Therapeutics (Amplia Therapeutics) 3-Year Book Growth Rate : -11.80% (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics 3-Year Book Growth Rate?

Amplia Therapeutics's Book Value per Share for the quarter that ended in Sep. 2023 was $0.05.

During the past 12 months, Amplia Therapeutics's average Book Value per Share Growth Rate was -22.10% per year. During the past 3 years, the average Book Value per Share Growth Rate was -11.80% per year. During the past 5 years, the average Book Value per Share Growth Rate was -7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 10 years, the highest 3-Year average Book Value per Share Growth Rate of Amplia Therapeutics was 1.60% per year. The lowest was -27.90% per year. And the median was -16.40% per year.

Competitive Comparison of Amplia Therapeutics's 3-Year Book Growth Rate

For the Biotechnology subindustry, Amplia Therapeutics's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's 3-Year Book Growth Rate falls into.

Amplia Therapeutics 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Amplia Therapeutics (OTCPK:INNMF) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Amplia Therapeutics 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (Amplia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

ATX:Australia

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines

From GuruFocus

AACR OVARIAN CANCER CONFERENCE PRESENTATION

By PRNewswire • 10-09-2023

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

By PRNewswire PRNewswire • 05-29-2023

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

By PRNewswire • 01-18-2024